BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel A, Sun W. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol. 2014;15:380-394. [PMID: 24838298 DOI: 10.1007/s11864-014-0291-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Sharma K, Suresh PS, Mullangi R, Srinivas NR. Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors - review of assay methodologies and perspectives: Review of quantitation of VEGFR2 inhibitors. Biomed Chromatogr 2015;29:803-34. [DOI: 10.1002/bmc.3370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
3 Cheng X, Zhang Y, Song F, Song F, Gao C, Liang X, Wang F, Chen Z. URM1 Promoted Tumor Growth and Suppressed Apoptosis via the JNK Signaling Pathway in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:8011-25. [PMID: 32848422 DOI: 10.2147/OTT.S258843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhang Z, Meng G, Wang L, Ma Y, Guan Z. The prognostic role and reduced expression of FOXJ2 in human hepatocellular carcinoma. Mol Med Rep 2016;14:254-62. [PMID: 27177166 DOI: 10.3892/mmr.2016.5261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Abdulrahman Almatrrouk S, Oliver AW, Hampson L, Hampson IN. Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis. Future Virology 2014;9:679-92. [DOI: 10.2217/fvl.14.50] [Reference Citation Analysis]
6 Liao Z, Wang X, Wang X, Li L, Lin D. DEPDC7 inhibits cell proliferation, migration and invasion in hepatoma cells. Oncol Lett 2017;14:7332-8. [PMID: 29344171 DOI: 10.3892/ol.2017.7128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Peng Y, Yu W, Li E, Kang J, Wang Y, Yang Q, Liu B, Zhang J, Li L, Wu J, Jiang J, Wang Q, Chang J. Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2′-Deoxyuridine for the Treatment of Hepatocellular Carcinoma. J Med Chem 2016;59:3661-70. [DOI: 10.1021/acs.jmedchem.5b01807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Yuan H, Liu F, Li X, Guan Y, Wang M. Angio-CT-Guided Transarterial Chemoembolization Immediately in Combination with Radiofrequency Ablation for Large Hepatocellular Carcinoma. Acad Radiol 2019;26:224-31. [PMID: 29907399 DOI: 10.1016/j.acra.2018.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis 2015;19:421-32. [PMID: 25921671 DOI: 10.1016/j.cld.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
10 Shao X, Lu Q, Wang G, Huang W, Yang L, Chen Z. Reduced expression of Nrdp1 predicts a poor prognosis in human hepatocellular carcinoma. Onco Targets Ther 2018;11:4955-63. [PMID: 30154664 DOI: 10.2147/OTT.S160638] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Mabrouk NMK, Elkaffash DM, Abdel-Hadi M, Abdelmoneim SE, Saad ElDeen S, Gewaifel G, Elella KA, Osman M, Baddour N. Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4. Drug Target Insights 2020;14:1-11. [PMID: 33132693 DOI: 10.33393/dti.2020.1548] [Reference Citation Analysis]
12 Kang HJ, Seol HS, Lee SE, Suh YA, Kim J, Jang SJ, Yu E. Guanabenz Acetate Induces Endoplasmic Reticulum Stress-Related Cell Death in Hepatocellular Carcinoma Cells. J Pathol Transl Med 2019;53:94-103. [PMID: 30646673 DOI: 10.4132/jptm.2019.01.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Li J, Shi L, Zhang X, Sun B, Yang Y, Ge N, Liu H, Yang X, Chen L, Qian H. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget. 2016;7:2646-2659. [PMID: 26544731 DOI: 10.18632/oncotarget.6104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
14 Jin Y, Lyu Y, Tang X, Zhang Y, Chen J, Zheng D, Liang Y. Lupeol enhances radiosensitivity of human hepatocellular carcinoma cell line SMMC-7721 in vitro and in vivo. International Journal of Radiation Biology 2015;91:202-8. [DOI: 10.3109/09553002.2015.966209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014; 6(12): 830-835 [PMID: 25544869 DOI: 10.4254/wjh.v6.i12.830] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
16 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
17 Hu B, Yang XB, Sang XT. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. Int Immunopharmacol 2021;90:107164. [PMID: 33172741 DOI: 10.1016/j.intimp.2020.107164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cao L, Zhang L, Zhao X, Zhang Y. A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One 2016;11:e0161025. [PMID: 27525972 DOI: 10.1371/journal.pone.0161025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Li Y, Tian Y, Zhong W, Wang N, Wang Y, Zhang Y, Zhang Z, Li J, Ma F, Zhao Z, Peng Y. Artemisia argyi Essential Oil Inhibits Hepatocellular Carcinoma Metastasis via Suppression of DEPDC1 Dependent Wnt/β-Catenin Signaling Pathway. Front Cell Dev Biol 2021;9:664791. [PMID: 34268303 DOI: 10.3389/fcell.2021.664791] [Reference Citation Analysis]
20 Chen Y, Liu F, Wu T, Sheu M. Antrodia cinnamomea Inhibits Migration in Human Hepatocellular Carcinoma Cells: The Role of ERp57 and PGK-1. Am J Chin Med 2016;43:1671-96. [DOI: 10.1142/s0192415x15500950] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]